Citigroup’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$811M Buy
2,096,863
+1,858,013
+778% +$689M 0.27% 70
2026
Q1
$69.9M Buy
238,850
+22,122
+10% +$7.27M 0.03% 523
2025
Q4
$76M Sell
216,728
-39,535
-15% -$13.4M 0.03% 470
2025
Q3
$82.8M Sell
256,263
-12,289
-5% -$3.82M 0.04% 440
2025
Q2
$104M Sell
268,552
-131,155
-33% -$52.8M 0.05% 335
2025
Q1
$174M Buy
399,707
+177,160
+80% +$71.1M 0.09% 207
2024
Q4
$82.1M Sell
222,547
-23,855
-10% -$9.98M 0.05% 344
2024
Q3
$128M Sell
246,402
-34,427
-12% -$18.4M 0.07% 226
2024
Q2
$152M Buy
280,829
+17,072
+6% +$9.02M 0.1% 187
2024
Q1
$137M Buy
263,757
+7,918
+3% +$3.94M 0.09% 211
2023
Q4
$121M Buy
255,839
+32,785
+15% +$15.2M 0.09% 211
2023
Q3
$97.1M Sell
223,054
-21,893
-9% -$9.93M 0.07% 241
2023
Q2
$109M Sell
244,947
-17,508
-7% -$8.08M 0.07% 214
2023
Q1
$121M Sell
262,455
-10,305
-4% -$4.9M 0.08% 185
2022
Q4
$140M Buy
272,760
+58,527
+27% +$29.7M 0.11% 166
2022
Q3
$97.3M Sell
214,233
-20,253
-9% -$9.69M 0.07% 227
2022
Q2
$113M Sell
234,486
-21,044
-8% -$10.4M 0.08% 194
2022
Q1
$126M Buy
255,530
+33,110
+15% +$15.1M 0.08% 235
2021
Q4
$103M Sell
222,420
-90,105
-29% -$37.9M 0.06% 315
2021
Q3
$117M Buy
312,525
+75,937
+32% +$28.9M 0.07% 249
2021
Q2
$90.3M Sell
236,588
-86,055
-27% -$32.9M 0.05% 328
2021
Q1
$116M Buy
322,643
+31,698
+11% +$10.2M 0.07% 240
2020
Q4
$93.4M Sell
290,945
-118,843
-29% -$36.5M 0.06% 299
2020
Q3
$110M Buy
409,788
+82,071
+25% +$22.1M 0.07% 220
2020
Q2
$86.2M Buy
327,717
+67,556
+26% +$18M 0.07% 254
2020
Q1
$59.1M Buy
260,161
+42,726
+20% +$11.6M 0.05% 306
2019
Q4
$65.7M Sell
217,435
-276,566
-56% -$76.1M 0.05% 384
2019
Q3
$119M Buy
494,001
+55,396
+13% +$15.2M 0.09% 189
2019
Q2
$124M Buy
438,605
+201,407
+85% +$55M 0.1% 185
2019
Q1
$68.1M Sell
237,198
-44,393
-16% -$12.8M 0.07% 281
2018
Q4
$74M Sell
281,591
-125,547
-31% -$34.5M 0.07% 262
2018
Q3
$112M Buy
407,138
+158,814
+64% +$41.2M 0.1% 175
2018
Q2
$59.1M Sell
248,324
-34,670
-12% -$8.03M 0.05% 307
2018
Q1
$62.2M Buy
282,994
+146,201
+107% +$34.3M 0.05% 325
2017
Q4
$30.8M Sell
136,793
-60,151
-31% -$12.8M 0.02% 626
2017
Q3
$37.4M Buy
196,944
+50,365
+34% +$9.59M 0.03% 506
2017
Q2
$27.6M Sell
146,579
-10,922
-7% -$1.96M 0.02% 615
2017
Q1
$26M Buy
157,501
+5,970
+4% +$950K 0.02% 639
2016
Q4
$21.8M Buy
151,531
+48,308
+47% +$6.47M 0.02% 727
2016
Q3
$12.9M Buy
103,223
+14,416
+16% +$1.86M 0.01% 913
2016
Q2
$11.7M Buy
88,807
+31,261
+54% +$4.28M 0.01% 945
2016
Q1
$8M Sell
57,546
-30,720
-35% -$4.11M 0.01% 1164
2015
Q4
$12.3M Sell
88,266
-11,301
-11% -$1.56M 0.01% 1009
2015
Q3
$13.9M Buy
99,567
+19,095
+24% +$2.87M 0.01% 917
2015
Q2
$13.2M Buy
80,472
+22,413
+39% +$3.58M 0.01% 1028
2015
Q1
$8.96M Buy
58,059
+11,451
+25% +$1.63M 0.01% 1263
2014
Q4
$5.86M Sell
46,608
-35,517
-43% -$4.39M 0.01% 1675
2014
Q3
$9.82M Sell
82,125
-25,425
-24% -$2.92M 0.01% 1290
2014
Q2
$11.6M Sell
107,550
-23,911
-18% -$2.46M 0.01% 1160
2014
Q1
$13.1M Sell
131,461
-24,799
-16% -$2.24M 0.01% 975
2013
Q4
$14.4M Sell
156,260
-40,629
-21% -$3.61M 0.01% 963
2013
Q3
$16.5M Buy
196,889
+11,210
+6% +$961K 0.02% 839
2013
Q2
$15.2M Buy
+185,679
New +$13.9M 0.02% 809

Other funds holding ELV

Citigroup's ELV Position: Q2 2026 in Review

Citigroup increased its Elevance Health (ELV) stake by 778% in Q2 2026, buying an estimated $689M and bringing the position to 2,096,863 shares worth $811M. The position accounts for 0.27% of the portfolio, ranked #70.

Citigroup first reported a position in ELV in Q2 2013 and has held it in 53 quarters since. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Citigroup held 2,096,863 shares of Elevance Health worth $811M as of Q2 2026.
  • Citigroup bought 1,858,013 Elevance Health shares in Q2 2026, an estimated $689M.
  • Elevance Health made up 0.27% of Citigroup's portfolio in Q2 2026, its #70 holding.
  • Citigroup first reported a position in Elevance Health in Q2 2013 and has held it in 53 quarters since.
  • 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.